Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Expands Ibrutinib Indications to Chronic GVHD

First FDA-approved therapy for the treatment of cGVHD
21 Aug 2017
Cancer in Special Situations/ Populations;  Cytotoxic Therapy
Haematological Malignancies

On 2 August 2017, the US Food and Drug Administration (FDA) approved ibrutinib (Imbruvica, Pharmacyclics LLC) for the treatment of adult patients with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy. This is the first FDA-approved therapy for the treatment of cGVHD.

Approval was based on study PCYC-1129-CA (NCT02195869), an open-label, multicentre, single-arm clinical trial enrolling 42 patients with cGVHD after failure of first-line corticosteroid therapy and requiring additional therapy. The majority of patients (88%) had at least two organs involved at baseline. The most common organs involved were mouth (86%), skin (81%), and gastrointestinal tract (33%).

Patients received ibrutinib orally at 420 mg once daily. Investigator-assessed overall response rate was 67%, or 28 patients (95% CI: 51%, 80%). The median time-to-response coinciding with the first scheduled response assessment was 12.3 weeks (range, 4.1 to 42.1 weeks). Responses were seen in all organs involved with cGVHD (skin, mouth, gastrointestinal tract, and liver). Responses lasting five months or longer were observed in 48% of the patients (n=20).

The most common adverse reactions (≥20%) were fatigue, bruising, diarrhoea, thrombocytopenia, stomatitis, muscle spasms, nausea, haemorrhage, anaemia, and pneumonia. Atrial fibrillation occurred in one patient (grade 3). Treatment was discontinued due to adverse reactions in 24% of the patients. The most common adverse reactions leading to discontinuation were fatigue and pneumonia. Adverse reactions leading to dose reduction occurred in 26% of patients.

FDA previously approved ibrutinib for the treatment of chronic lymphocytic leukaemia/small lymphocytic lymphoma, chronic lymphocytic leukaemia/small lymphocytic lymphoma with 17p deletion, Waldenström’s macroglobulinemia, marginal zone lymphoma, and mantle cell lymphoma.

The recommended dose of ibrutinib for cGVHD is 420 mg taken orally once daily (three 140 mg capsules once daily).

Full prescribing information is available here.

FDA granted Breakthrough Therapy and Orphan Drug designations to ibrutinib for this indication, as well as priority review.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

Last update: 21 Aug 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.